

Disclosure according to Article 5 Section (1) and (6) of the EU Regulation 596/2014 in conjunction with Article 2 Section (2) and (3) of the Delegated EU Regulation 2016/1052 / Share Repurchase – Completion Reporting

With disclosure dated September 5, 2018, QIAGEN N.V. announced pursuant to Article 5 Section (1) and (6) of the EU Regulation no 596/2014 and Article 2 Section (1) of the Delegated EU Regulation no 2016/1052 the immediate beginning of a first tranche of up to USD 50 million under the share repurchase program originally announced on January 31, 2018.

In the context of this tranche the final shares have been bought back on the electronic trading platform of the Frankfurt Stock Exchange (XETRA) from October 15, 2018 until and including October 17, 2018 amounts to 190,065 shares.

Shares were bought back as follows:

Date	Number of Shares acquired	Average Price (EUR)	Purchased Volume (EUR)
15- October -2018	64,472	29.6095	1,908,983.68
16- October -2018	63,099	30.2538	1,908,984.53
17- October -2018	62,494	30.4550	1,903,254.77
Total	190,065	30.1014	5,721,222.98

The underlying individual trades are published on the website of QIAGEN N.V. (<http://corporate.qiagen.com/investor-relations/share-information/share-buyback>).

The total number of shares which have been bought back within the framework of such tranche of the share repurchase program from September 5, 2018 until and including October 17, 2018 amounts to 1,370,211 shares. The average purchase price per share was EUR 31.56 a total price of EUR 43,245,082.90 (excl. ancillary costs), which represents based on the ECB reference rate as of 04 September 2018 (EUR 1 = USD 1.1562) a USD amount of 49,999,964.85 was paid to buy back the shares.

The purchase of the shares of QIAGEN N.V. was carried out by a financial institution that has been commissioned by QIAGEN N.V.

We will report on the execution of further tranches of the buy-back program in due course.

Venlo, 23 October 2018

Managing Board

###

Contacts:

QIAGEN

Investor Relations

John Gilardi
e-mail: ir@qiagen.com

+49 2103 29 11711

Public Relations

Dr. Thomas Theuringer
e-mail: pr@qiagen.com

+49 2103 29 11826